BOCIC(SH:601696) Xin Lang Cai Jing·2025-08-27 02:57Group 1 - Yifang Biotechnology experienced a decline of 5.03% on August 27, with a stock price of 37.96 yuan per share and a trading volume of 326 million yuan, resulting in a turnover rate of 2.00% and a total market capitalization of 21.953 billion yuan [1] - Yifang Biotechnology (Shanghai) Co., Ltd. was established on January 11, 2013, and went public on July 25, 2022. The company focuses on the research, production, and sales of innovative drugs, with its main revenue source being technology licensing and cooperation, accounting for 100.00% of its revenue [1] Group 2 - According to data from the top ten holdings of funds, a fund under Bank of China Securities has a significant position in Yifang Biotechnology. The Bank of China Health Industry Mixed Fund (002938) reduced its holdings by 260,000 shares in the second quarter, retaining 450,000 shares, which represents 9.35% of the fund's net value, making it the largest holding [2] - The Bank of China Health Industry Mixed Fund (002938) was established on September 7, 2016, with a current size of 158 million yuan. It has achieved a return of 64.65% year-to-date, ranking 202 out of 8,194 in its category, and a return of 71.31% over the past year, ranking 1,014 out of 7,963 [2] - The fund manager, Li Mingwei, has been in charge for 2 years and 188 days, with the fund's total asset size at 158 million yuan. The best and worst returns during his tenure are both recorded at 10.78% [2]